The transcription factor CCAAT enhancer-binding protein a (C/EBPa) has an important role in granulopoiesis. The tumor suppressor function of C/EBPa is shown by the findings that loss of expression or function of C/EBPa in leukemic blasts contributes to a block in myeloid cell differentiation and to leukemia. C/EBPa mutations are found in around 9% of acute myeloid leukemia (AML) patients. The mechanism by which the mutant form of C/EBPa (C/EBPa-p30) exerts a differentiation block is not well understood. By using a proteomic screen, we have recently reported PIN1 as a target of C/EBPa-p30 in AML.
Introduction
The transcription factor CCAAT enhancer-binding protein a (C/EBPa) is a critical regulator of the myeloid differentiation program. Recent studies on animal models and acute myeloid leukemia (AML) patient samples suggest that the loss of function or expression of C/EBPa provides a platform on which AML develops.
1 C/EBPa is mutated in about 9% of AML samples. 2 The mutations reported in C/EBPa are point mutations in the basic region or in the leucine zipper domain and frame shift mutations in the N-terminal domain, which result in the expression of the shorter form of C/EBPa, C/EBPa-p30. 3, 4 C/ EBPa-p30 is produced by alternative transcription initiation. It retains the DNA-binding domain, but lacks the N-terminal transactivation domain of the longer form of C/EBPa, C/EBPap42. C/EBPa-p30 fails to induce differentiation and exhibits a dominant-negative function over C/EBPa-p42. The expression of the p30 isoform is high in AML patients with C/EBPa mutations. A recent study has shown the ability of C/EBPa-p30 to induce AML in a mouse model. 5 Using a proteomic approach, we have recently shown that one of the mechanisms behind the dominant-negative function of C/EBPa-p30 is through increased sumoylation of C/EBPa-p42 by UBC9. 6 In this screen, we also identified the peptidyl-prolyl cis/trans isomerase, PIN1, as one of the transcriptional target genes of C/EBPa-p30. PIN1 binds to and isomerizes the peptidyl-prolyl bond in serine or threonine-phosphorylated Ser/Thr-Pro motifs. 7 ,8 PIN1 appears to be important in tumorigenesis because it has been found to be overexpressed in many cancers including prostate, lung, ovary, cervical, breast, brain and skin cancers. 9, 10 Although Pin1-null animals display age-dependent defects, no other phenotypic characteristics related to cancer have been detected. 11 Mice lacking Pin1 are resistant to tumorigenesis induced by oncogenic Neu or Ras. 12 The inhibition of PIN1 in cancer cells by multiple approaches triggers apoptosis or suppresses the transformed phenotype. 13, 14 Indirect evidence for the role of PIN1 in leukemia comes from its positive effect on the transcriptional activity of c-Jun, 10 ,15 a protooncogene shown by our lab to be downregulated by C/EBPa-p42 during granulopoiesis. 16 We have also shown that c-Jun is overexpressed in AML patients with C/EBPa mutations. 17 Furthermore, growing number of studies support the oncogenic potential of PIN1, which is an E2F1 target. 18 Interestingly, E2F1 inhibition by C/EBPa is a critical step in myeloid differentiation. 19 However, the exact role of PIN1 in leukemogenesis remains elusive.
In the present study, we investigated the role of PIN1 in AML with C/EBPa mutation. We provide evidence that C/EBPa-p30 upregulates PIN1 protein levels. AML patients show high PIN1 expression. We show that silencing PIN1 leads to granulocytic differentiation of primary AML blasts derived from patients with C/EBPa mutations and also in leukemic cell lines. Furthermore, we show that PIN1 prevents degradation of c-Jun, which in turn blocks C/EBPa-induced differentiation.
Materials and methods

Cells, transfections and reagents
Kasumi-6 cells were obtained from ATCC (Manassas, VA, USA). Blast cells from AML patients were obtained from the Laboratory for Leukemia Diagnostics at the University of Munich, Germany.
All samples were karyotyped and molecular genetic analysis was performed for C/EBPa mutations. Before therapy, all patients gave their informed consent for participation in the Acute Myeloid Leukemia Cooperative Group (AMLCG) studies. Details of the study protocol have been published.
20
K562-C/EBPa-p42-ER and K562-C/EBPa-p30-ER cells 21 were maintained in RPMI 1640 medium without phenol red, supplemented with 10% charcoal-treated fetal bovine serum, 1% penicillin-streptomycin and 2 mg/ml puromycin; Kasumi-6 cells 22 were cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum, 1% penicillin-streptomycin and 2 ng/ ml granulocyte-macrophage colony-stimulating factor; AML blast cells were cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); U937 cells and NB4 cells were cultured in RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.
K562-C/EBPa-p30-BRM2-ER cells were established as reported before. 21 Briefly, C/EBPa-p30 was amplified by PCR using rat C/EBPa having BRM2 mutation (kind gift from Bruno Calabretta) with BamHI flanking primers (forward primer 5 0 -GGGGATCCGCCACCATGTCCGCGGGGGCGCAC-3 0 and reverse primer 5 0 -ATGGATCCGGCGCGCAGTTG-3 0 ) and subsequently cloned into pBabe-ER digested with BamHI with the 30-KDa C/EBPa peptide in frame with the C-terminal endoplasmic reticulum (ER) domain. K562 cells (10 6 cells) were electroporated with AMAXA transfection method with 3 mg of ScaI-linearized plasmid and plated on six-well plate containing phenol red-free RPMI/10% charcoal-treated fetal bovine serum medium. Selection with 1 mg/ml puromycin began 48 h after transfection.
Cells (2 Â 10 4 293T cells) were transfected with the Lipofectamine Plus reagent (Invitrogen, Karlsruhe, Germany) according to manufacturer's instruction. Transfection of U937 and Kasumi-6 cells was performed with the Nucleofector kit (AMAXA, Cologne, Germany) as described by the manufacturer. Plasmid DNA (2 mg) was used for each transfection, and the transfection efficiency was analyzed using a plasmid with enhanced green fluorescent protein marker. U937 and Kasumi-6 cells were transfected with nucleofection programmes V-01 and T-03, respectively. Transfection efficiencies of around 55-70% and 66-75% were observed in these cell lines, respectively.
Peptidyl-prolyl isomerase-parvulin inhibitor PiB (Calbiochem, Darmstadt, Germany) was prepared in ethanol and used at a concentration of 5 mM. C/EBPa small interfering RNA (siRNA) was purchased from Invitrogen.
Proteomics screening
To induce C/EBPa-p30, K562-C/EBPa-p30-ER cells were treated with 5 mM of b-estradiol for 6 h followed by lysis. The protein identification by mass spectrometry was carried out essentially, as reported before. 6 
Promoter assay
Cells (293T cells) were transiently transfected using lipofectamine (Invitrogen) as described by the manufacturer. Firefly luciferase activities from the PIN1 promoter constructs and Renilla luciferase activity from the internal control plasmid pRLnull were determined 24 h after transfection using the DualLuciferase Reporter Assay System (Promega, Mannheim, Germany). Firefly luciferase activities were normalized to the Renilla luciferase values of pRL-null.
Immunoblot analysis
Immunoblot analysis was performed with 50 mg total protein lysates using anti-C/EBPa (sc-61), anti-PIN1 (sc-15340), antic-Jun (sc-1694), anti-b-tubulin (sc-9104) and anti-E2F1 (sc-251) antibodies from Santa Cruz Biotechnology, Heidelberg, Germany. The immunodetection was performed using an ECL reagent (Amersham Biosciences, Freiburg, Germany). The band intensities were quantified using ImageJ software (National Institute of Health, Bethesda, MD, USA).
Chromatin immunoprecipitation
The crosslinking of proteins to DNA was accomplished by the addition of 1% formaldehyde for 10 min to cultured cells (6 Â 10 6 cells) at 37 1C. After sonication, the chromatin was immunoprecipitated with 5 mg of the antibodies anti-E2F1 (sc-193X) or anti-IgG (SC-2027, Santa Cruz) at 4 1C overnight.
Flow cytometry analysis
For flow cytometry analysis, 10 6 cells were washed twice with phosphate-buffered saline and resuspended in 50 ml of phosphatebuffered saline with 2 ml of the respective antibody. Incubation was performed for 20 min in ice. After the incubation, cells were washed with phosphate-buffered saline, resuspended in phosphate-buffered saline and analyzed by flow cytometry on a FACScan (Becton Dickinson, Heidelberg, Germany).
mRNA expression analysis
Total RNA was isolated from leukemic patient samples, processed and analyzed on the Affymetrix HG-U133A and HG-U133B chips (Affymetrix, Santa Clara, CA, USA), as described before. 23 The data from Affymetrix analysis were normalized according to the procedure described before. 24 Normalized expression data were then analyzed with the R software package and the 'boxplot' function (www.r-project.org). Expression signal intensities are expressed on a logarithmic scale.
Real-time reverse transcription-PCR
Total RNA was isolated from cells with Trizol reagent (Invitrogen). RNA (750 ng) was used to synthesize cDNA by reverse transcription. Equal amounts of cDNA were taken for a subsequent quantitative real-time PCR using the SYBR Green PCR kit (Qiagen, Hilden, Germany) in a Rotor-Gene RG-3000 cycler (Corbett Research, Sydney, Australia). The fold change was calculated using delta C T method reported before. 25 
Protein stability assay
Cells (293T cells) were transfected with 6.6 mg of PIN1 or nonsilencing siRNA (Qiagen) using lipofectamine. After 24 h, cells were treated with cyclohexamide (100 mg/ml) for various periods and lysed. The amount of c-Jun protein was analyzed by western blot and quantified by densitometric scanning.
Ubiquitination assay
Cells (293T cells) were transiently transfected with different constructs, as described for promoter assay; at 24 h after transfection, cells were lysed in radio immunoprecipitation assay buffer followed by c-Jun immunoprecipitation from 500 mg total protein. The protein samples after immunoprecipitation were analyzed in a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel and probed with an hemagglutinin antibody (Roche Applied Science, Mannheim, Germany).
Statistical analysis
We used Student's t-tests to determine the statistical significance of experimental results. A P-value of 0.05 or less was considered significant.
Results
C/EBPa-p30 induces PIN1 expression in leukemia
The K562-ER cell line is an early multipotential cell line derived from the K562 cell line, which was originally obtained from a patient with chronic myeloid leukemia. To derive the K562-ER cell line, K562 cells were stably transfected with a plasmid encoding an estrogen-inducible C/EBPa-p30 estrogen receptor fusion protein (C/EBPa-p30-ER).
21 K562-ER cells have been shown to be a good model system to study granulopoiesis in the context of C/EBPa proteins ( Supplementary Figures 1 and 2 ). We have previously reported a proteomic approach for the identification of C/EBPap30 target proteins in C/EBPa-p30-ER cell line. 6 In this screen, PIN1 was identified as one of the targets of C/EBPa-p30 ( Figure 1a) .
As a first step to elucidate the importance and role of PIN1 as a target of C/EBPa-p30, we investigated the PIN1 mRNA levels in leukemic patient samples. Affymetrix analysis showed that PIN1 mRNA expression is increased in different subtypes of leukemia compared with normal bone marrow controls ( Figure 1b) . We also observed elevated PIN1 levels in AML samples with C/EBPa mutation in comparison with AML samples without C/EBPa mutation ( Figure 1c ). The increased expression of PIN1 in different leukemic subtypes suggests that mechanisms other than C/EBPa mutations can increase PIN1 levels (see Discussion). Next, we examined the ability of C/ EBPa-p30 to induce PIN1 protein expression in the K562-C/ EBPa-p30-ER cell line. Our data revealed that PIN1 protein expression was upregulated by C/EBPa-p30 during b-estradiol induction (Figure 1d left, Supplementary Figure 3 ). These data confirm our proteomic findings and reveal the relevance of PIN1 as a target in leukemia. We also investigated regulation of PIN1 during C/EBPa-p30 overexpression in two AML cell linesFKasumi-6 (C/EBPa mutation positive) and NB4 (C/EBPa mutation negative). We observed that C/EBPa-p30 is able to upregulate PIN1 (Supplementary Figure 4) . We observed slightly lower expression of PIN1 in Kasumi-6 cells in comparison with NB4 cells (Supplementary Figure 4) . Similar to the upregulation of PIN1 protein levels, we observed an upregulation of PIN1 mRNA levels on C/EBPa-p30 induction (Supplementary Figure 5) .
C/EBPa-p42 and C/EBPa-p30 have been shown to have different biological properties. 3 On the basis of our finding that C/EBPa-p30 is able to induce PIN1 expression, we asked whether C/EBPa-p42 is able to regulate PIN1 protein levels. Our data show that in contrast to the C/EBPa-p30 form, C/EBPa-p42 repressed PIN1 protein levels (Figure 1d , right). This shows that C/EBPa-p42 and C/EBPa-p30 have opposing effects on PIN1 protein levels. We could not find any regulation of PIN1 during C/EBPa-p42 silencing by siRNA (supplementary Figure 4) . Hence, we assume that silencing of C/EBPa-p42 alone is not sufficient for the regulation of PIN1.
We also analyzed the role of C/EBPa with mutations in the E2F1 protein-binding domain (C/EBPa-BRM2) 21, 26 in regulating PIN1 protein expression. Our data suggest that C/EBPa-BRM2 fails to downregulate PIN1 protein levels (data not shown). This denotes that E2F1 interaction of C/EBPa-p42 is necessary for its inhibitory action over PIN1.
C/EBPa-p30 induces PIN1 promoter activity in association with E2F1
It has been previously shown that there are three E2F1-binding sites in the PIN1 promoter and E2F1 can transactivate PIN1 promoter activity. 27 As we observed that C/EBPa-p30 induces PIN1 expression, we next investigated how C/EBPa proteins regulate PIN1 transcription. To address this, we performed promoter assays in the human embryonic kidney cell line 293T with different PIN1 promoter constructs. 27 Our data revealed that overexpression of E2F1 could transactivate PIN1 promoter, as published before (Figure 2a To determine the importance of the three E2F1-binding sites for the C/EBPa-p30 cooperation with E2F1 in regulating PIN1 promoter activity, we performed promoter assays with different deletion mutants of PIN1 promoter (Figure 2b) . Compared with the wild-type PIN1 promoter vector (À2300 Luc), deletion of the E2F1-binding sites (sites located at À557 to À550, À312 to À305 and at À288 to À281) exhibited decrease in the PIN1 promoter activity in a site-dependent manner (Figure 2c ). These data suggest that E2F1-binding sites are important for the association of C/EBPa-p30 with E2F1.
To gain further insights into the mechanism of association of C/EBPa-p30 with E2F1 in regulating PIN1 expression, we performed chromatin immunoprecipitation assays in K562-C/EBPa-p30-ER cells. Cells were treated with b-estradiol to induce C/EBPa-p30 and chromatin fragments were immunoprecipitated with an anti-E2F1 antibody. DNA from the immunoprecipitates was PCR amplified using primers flanking the two E2F1-binding sites PIN1 promoter region shown in Figure 2d . We observed increased binding of E2F1 during C/EBPa-p30 induction in a time-dependent manner ( Figure 2e ). We analyzed whether increased binding of E2F1 in the PIN1 promoter is associated with induction of E2F1. Our data show that C/EBPa-p30 does not induce E2F1 protein (Supplementary Figure 6) . It has been previously shown that C/EBPa-p30 is able to interact with E2F protein. 21 To evaluate whether interaction of C/EBPa-p30 with E2F1 has a role in the induction of PIN1 by C/EBPa-p30, we analyzed induction of PIN1 in a cell line that has mutation in the E2F1-interacting domain of C/EBPa-p30. Our data show that that E2F1 interaction is not needed for PIN1 induction (Supplementary Figure 7 ). Taken together, our data show that induction of C/EBPa-p30 leads to a recruitment of E2F1 to the PIN1 promoter and this is independent of interaction of C/EBPa-p30 with E2F1. These data suggest that PIN1 might represent an important target of E2F1 activation in the C/EBPa-p30-induced differentiation block. We also analyzed binding of C/EBPa-p30 to the PIN1 promoter in a similar experimental setting. We did not observe any binding of C/EBPa-p30 to the PIN1 promoter (data not shown).
To find the possibility of C/EBPa-p30 cooperation with E2F1 in regulating other E2F1 target genes, we performed chromatin immunoprecipitation in K562-C/EBPa-p30-ER cells for c-Myc promoter (Supplementary Figure 8) . Even though we observed a slight increase in E2F1 binding in c-Myc promoter during C/ EBPa-p30 induction, the effects were minor. This suggests that cooperation of C/EBPa-p30 with E2F1 is more effective in the regulation of PIN1 expression.
PIN1 inhibition by PiB can overcome the differentiation block observed in human myeloid cells
To further understand how silencing of the PIN1 activity is biologically significant in the context of C/EBPa mutation, we carried out myeloid differentiation experiments in AML blast cells with C/EBPa mutation and in Kasumi-6 cells. Kasumi-6 is a myeloid leukemia cell line established from the bone marrow cells of an individual with AML, subtype M2 having C/EBPa mutation and endogenously expressing both the p42 and the p30 isoforms of the C/EBPa protein. 22 For silencing PIN1, we used the PIN1 inhibitor, PiB. 28 PiB has been shown to inhibit the PIN1 activity by binding to the peptidyl-prolyl cis/trans isomerase domain of PIN1. The myeloid cell differentiation was assessed by CD11b and CD15 expression by flow cytometry analysis, as well as by the level of granulocyte colonystimulating factor receptor (G-CSFR) expression by real-time reverse transcription-PCR. Treatment of AML blast cells and the Kasumi-6 cells with PiB induced myeloid differentiation ( Figure 3 ). We did not observe any significant change in granulocyte morphology during PIN1 inhibition by PiB (data not shown). Hence, we assume that PIN1 inhibition by PiB is not sufficient to induce terminal stages of differentiation. We investigated the role of PIN1 silencing in NB4 cells, which do not have any C/EBPa mutation. We observed that PIN1 inhibition in NB4 cells leads to granulocytic differentiation (Supplementary Figure 9) . However, compared with Kasumi-6, the differentiation effects were modest during PIN1 silencing in NB4 cells. We also analyzed the effect of PIN1 silencing in normal bone marrow cells. We did not observe any change in granulocytic differentiation (data not shown). These data suggest that C/EBPa mutation status (presence of C/EBPa-p30) is significant in granulocytic differentiation during PIN1 silencing. The granulocytic differentiation during PIN1 inhibition by PiB was found to be independent of apoptosis (Supplementary Figure 10 ) and cell proliferation (data not shown).
PIN1 blocks granulocytic differentiation
The C/EBPa-p30 has been shown to block granulocytic differentiation mediated by C/EBPa, 3 as well as to be able to induce AML. 5 On the basis of our data that C/EBPa-p30 induces PIN1 in AML (Figure 1 ) and silencing PIN1 leads to granulocytic differentiation (Figure 3) , we assessed the ability of PIN1 to block granulocytic differentiation. We overexpressed PIN1 in myeloid U937 cells and treated the cells with retinoic acid to induce granulocytic differentiation. Overexpression of PIN1 blocked granulocytic differentiation, as shown by around 50% reduction in CD15 expression as well as reduction in G-CSFR expression (Figure 4) . Taken together, these data show that PIN1 could have significant role in granulocytic differentiation block observed in AML.
PIN1 controls the stability of the c-Jun protein
We have previously reported that c-Jun expression is high in AML patient samples with C/EBPa mutation. 17 On c-Jun Nterminal kinase activation, PIN1 binds to c-Jun, which is phosphorylated on Ser63/73-Pro motifs. 10 Owing to the fact that C/EBPa-p30 could induce PIN1 and that PIN1 regulates the protein stability of many targets with which it interacts, 8 we hypothesized that PIN1 could have a significant role in regulating c-Jun protein stability. To test this hypothesis, PIN1 expression was silenced in 293T cells by RNA interference and c-Jun protein stability was then assessed by blocking protein synthesis with cyclohexamide and by measuring the c-Jun protein remaining at various time points. Our data show that the stability of c-Jun was reduced when PIN1 expression was knocked down by a specific siRNA (Figure 5a and supplementary Figure 11 ). These results indicate that PIN1 is an important factor in regulating the stability of c-Jun protein.
PIN1 protects c-Jun from ubiquitination-mediated protein degradation
c-Jun has been shown to be subjected to ubiquitin-mediated degradation in a c-Jun N-terminal kinase-dependent manner. On the basis of our finding that PIN1 regulated c-Jun protein stability (Figure 5a) , we tested the role of PIN1 in the degradation of c-Jun. We performed ubiquitination assays in 293T cells by overexpressing c-Jun, PIN1 and hemagglutinintagged ubiquitin. When c-Jun was cotransfected with hemagglutinin-tagged ubiquitin, higher molecular weight bands were detected in the immunoprecipitation with the hemagglutinin antibody, which reflects c-Jun ubiquitination (Figure 5b, lane 4) . Interestingly, when PIN1 was cotransfected, the ubiquitination of c-Jun was prevented, suggesting a role for PIN1 in the regulation of c-Jun degradation (Figure 5b, lane 5) .
Our data suggest that PIN1 prevents the degradation of c-Jun protein (Figure 5a, b) . The Jun protooncogene is positively autoregulated by its product, Jun/AP-1. 31 On the basis of these findings, we hypothesized that PIN1 could have a major role in regulating c-Jun mRNA levels. We overexpressed PIN1 in Kasumi-6 cells and analyzed c-Jun mRNA levels by quantitative real-time reverse transcription-PCR. We observed that overexpression of PIN1 leads to an increase in c-Jun mRNA levels (Supplementary Figure 12a) . We next investigated the effect of silencing PIN1 on the c-Jun mRNA levels. We found that silencing PIN1 with the inhibitor PiB downregulated the c-Jun mRNA level (Supplementary Figure 12b) . These data show that PIN1 stabilizes c-Jun protein, which in turn induces c-Jun mRNA by autoregulation.
c-Jun blocks granulocytic differentiation
We have previously shown that downregulation of the protooncogene c-Jun by C/EBPa is important for granulocytic lineage commitment. 16 We have also reported that c-Jun expression is high in different subtypes of AML including AML samples with C/EBPa mutation and that c-Jun is able to block the DNA binding of C/EBPa. 17 On the basis of these findings, we hypothesized that c-Jun is able to block the granulocytic differentiation induced by C/EBPa. To assess this, we overexpressed c-Jun in human myeloid U937 cells and treated the cells with retinoic acid. The granulocyte differentiation was assessed by FACS (fluorescence activated cell sorting) analysis for CD15 expression and by quantitative real-time reverse transcription-PCR for G-CSFR. The expression of CD15 during granulocytic differentiation was downregulated to around threefold in the presence of c-Jun (Figure 5c ). The myeloid markers such as G-CSFR were also found to be downregulated during overexpression of c-Jun (Figure 5c ). These data suggest that c-Jun is able to block granulocytic differentiation induced by C/EBPa.
Discussion
Initially, it was suggested that the dominant-negative effect of C/ EBPa-p30 is the result of heterodimerization of the mutant form with the C/EBPa-p42. A recent report shows that a C/EBPa-p30 with modification in the leucine zipper, which cannot form heterodimers with C/EBPa-p42, still exhibits dominant-negative properties over C/EBPa-p42. 32 This suggests that rather than heterodimerization, regulatory networks activated by C/EBPap30 could have a critical role in its dominant-negative function. One recent study showed that C/EBPa-p30 has quite distinct functional properties compared with the C/EBPa-p42. 33 This study showed that C/EBPa-p30 is able to bind to a unique set of target genes with higher affinity than did C/EBPa-p42. Mice with targeted disruption of C/EBPa-p42, which express C/EBPa-p30, develop leukemia. 5 This finding is of particular interest as C/ EBPa knockout mice did not develop leukemia even though they exhibited a block of granulocytic differentiation. 34 Taken together, these findings show that the disruption of C/EBPa-p42 alone is not sufficient to initiate leukemogenesis, but that pathways modulated by C/EBPa-p30 might be critical in the development of AML.
By using a proteomic screen, we have recently shown that C/ EBPa-p30 is able to upregulate the expression of a number of proteins including PIN1. 6 Our finding that PIN1 is upregulated in leukemic patient samples including in those with C/EBPa mutations (Figure 1b,c) is intriguing as PIN1 overexpression was shown to amplify multiple signaling pathways important in oncogenesis. 35 We have shown that C/EBPa-p42 is able to downregulate PIN1 protein levels (Figure 1d, right) . One possible explanation for the upregulation of PIN1 in different leukemic samples could be that C/EBPa has been shown to be downregulated by diverse mechanisms in different subtypes of leukemia. 36 This downregulation of C/EBPa function might then lead to PIN1 overexpression in leukemia (Figure 1b) . However, we did not find any significant upregulation of PIN1 during C/ EBPa silencing in cell lines (Supplementary Figure 4) . It has been observed that BRCA1 tumor suppressor (breast cancer-associated gene 1) represses PIN1. 37 Women with germline heterozygous mutations in BRCA1 are at increased risk of developing breast cancers 38 and PIN1 is overexpressed in breast cancer. 10 These findings suggest the possibility that other tumor suppressors could also be regulating PIN1 expression in granulopoiesis. Further studies are needed to show how C/EBPa as well as other tumor suppressors regulate PIN1 and how PIN1 is overexpressed in AML without C/EBPa mutation.
A recent study proposes that C/EBPa could be a PIN1 target. 39 This study points out that several Ser/Thr-Pro motifs in C/EBPa could be regulated by PIN1-mediated isomerization. Most of the Ser/Thr-Pro motifs in the C/EBPa-p42 are also present in C/EBPap30. Even though C/EBPa has been shown to be phosphorylated, there is no report about PIN1-mediated post-phosphorylation mechanisms regulating the C/EBPa function. Further studies are needed to explain how PIN1 regulates C/EBPa-mediated transactivation and whether CEBPA might be a target of PIN1-mediated proline isomerization. In granulopoiesis, the inhibition of the E2F1 activity has been proven to be the unique mechanism for the antimitotic activity of C/EBPa. 19, 40 E2F1 activates the transcription of the MYC oncogene, which had been shown to block granulopoiesis. C/ EBPa inhibition of E2F1 has been shown to result in the downregulation of c-Myc, leading to granulopoiesis. 41 This raises the possibility that other E2F1 targets could also be regulated by C/EBPa in a similar mechanism, as observed for c-Myc. In this context, it should be noted that PIN1 has been shown to be an E2F1 target gene, 27 and lack of E2F inhibition by C/EBPa has been shown to be a key event in AML. 5, 42 Our finding that C/EBPa interferes with the E2F1 transactivation of PIN1 promoter (Figure 2a) suggests that the downregulation of PIN1 by C/EBPa could be an important event in granulopoiesis. Our observation points out the intrinsic differences between C/EBPa-p42 and C/EBPa-p30 in regulating PIN1 expression. C/EBPa-p30 cooperates with E2F1 in regulating PIN1 promoter activity (Figures 2a, c) , and C/EBPa-p30 is capable of recruiting E2F1 to the PIN1 promoter (Figure 2e ). This suggests that regulatory networks coordinated by C/EBPa-p30 and E2F1 could have an important role in AML with C/EBPa mutations.
A recent study shows that C/EBPa-p30 not only blocks granulopoiesis but also has the potential to induce AML. 5 This study also indicates that loss of C/EBPa function alone is not sufficient for the development of AML. Rather, a restricted modulation of C/EBPa-p42 function by C/EBPa-p30 is a prerequirement for AML to develop. Our findings that C/EBPa-p30 induces PIN1 (Figure 1) , inhibition of PIN1 leads to granulocytic differentiation ( Figure 3 ) and that PIN1 blocks granulopoiesis (Figure 4) , point out the fact that PIN1 might have a major role in contributing to the differentiation block observed during C/EBPa mutation.
PIN1 is overexpressed in breast cancer and increases the transcriptional activity of c-Jun.
10 PIN1 regulates the protein degradation of many targets with which it interacts, including p53, p73, nuclear factor-kB and cyclin D1. 8 In addition, PIN1 has been shown to bind to c-Jun 10 and has been proposed to increase the protein stability of c-Jun. 8 Our data show that PIN1 increases the stability of c-Jun protein by inhibition of its ubiquitination (Figure 5a,b) . As observed for other PIN1 targets, we assume that stabilization of c-Jun by PIN1 is a general phenomenon in cancer. c-Jun is an effector of many signal cascades and has crucial functions in diverse mechanisms of oncogenesis. 43 An oncogenic role for c-Jun in AML was suggested by the finding that c-Jun is overexpressed in different subtypes of AML. 17, 44 One explanation for the upregulation of c-Jun expression in AML might be the downregulation of C/EBPa by different mechanisms. 36 Furthermore, leukemic fusion proteins such as BCR-ABL 45 and AML1-ETO 44 have been shown to induce c-Jun expression through the c-Jun N-terminal kinase signaling pathway. We cannot rule out the possibility that loss of activity of other factors that negatively regulate PIN1 could also upregulate c-Jun in AML. Our laboratory had shown that c-Jun inactivates C/EBPa through direct protein-protein interaction through their leucine zipper domains. 17 One recent study suggested that C/EBPa-c-Jun interaction has the potential to induce monocytic differentiation, 46 pointing out how proteinprotein interactions of C/EBPa are critical in lineage commitment decisions. Another report showed that c-Jun has the ability to promote monocytic differentiation at the expense of granulocytic differentiation. 47 Our data also indicate that overexpression of c-Jun induces monocytic differentiation (Supplementary Figure 13) . Our findings that PIN1 can stabilize c-Jun (Figure 5a ) and prevent c-Jun ubiquitination (Figure 5b ) suggest that PIN1 might have an important role in regulating the c-Jun protein turn over. The stabilized c-Jun might bind to its own promoter and increase its expression in a positive feedback loop. 31 The ability of c-Jun to block DNA binding of C/EBPa, 17 as well as our finding that c-Jun is able to inhibit granulocytic differentiation (Figure 5d ), suggests a model in which c-Jun promotes proliferation and leads to differentiation block by inactivating C/EBPa. In other words, the relative protein concentrations of C/EBPa and c-Jun regulate granulopoiesisFhigher C/EBPa levels favor differentiation, whereas higher c-Jun levels favor proliferation. In summary, our study identifies PIN1 as an important player that might contribute to myeloid leukemia development through the inhibition of the C/EBPa function. Here, we show that PIN1 is upregulated by C/EBPa-p30 and that silencing of PIN1 is able to overcome the differentiation block mediated by C/EBPa-p30. Our observations suggest a model in which C/EBPa-p30 induces PIN1 expression and increases the stability of c-Jun, which in turn inhibits the function of C/EBPa-p42 ( Figure 6 ). Inhibiting PIN1 function could provide a novel strategy in the treatment of myeloid leukemic patients. Figure 6 Model depicting the PIN1-mediated dominant-negative role of C/EBPa-p30 in AML with C/EBPa mutation. C/EBPa-p30 cooperates with E2F1 and increases the PIN1 mRNA and protein levels. PIN1 stabilizes the c-Jun protein, which in turn blocks C/EBPa functions and leads to differentiation block and AML.
